Showing results (301-310 of 319) with videos related to
Sort By:
Pageof 32
Plos Genetics|October 3, 2009
Oncogenic pathway combinations predict clinical prognosis in gastric cancerChia Huey Ooi, Tatiana Ivanova, Jeanie Wu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2019
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyAurelien Marabelle, Dung T Le, Paolo A Ascierto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" TrialWei Peng Yong, Sun Young Rha, Iain Bee-Huat Tan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid TumorsJoaquin Mateo, Gopinath Ganji, Charlotte Lemech, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 20, 2021
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumabNarikazu Boku, Taroh Satoh, Min-Hee Ryu, et al.Lancet (London, England)|October 11, 2017
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Narikazu Boku, Taroh Satoh, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 16, 2019
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancerTaroh Satoh, Yoon-Koo Kang, Yee Chao, et al.The Lancet. Gastroenterology & Hepatology|June 21, 2024
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Masanori Terashima, Young-Woo Kim, et al.JAMA Oncology|September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical TrialKohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.Oncotarget|April 19, 2017
Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancerHyo Song Kim, Hanna Lee, Su-Jin Shin, et al.Pageof 32